Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Solasia Pharma KK ( (JP:4597) ).
Solasia Pharma has revised downward its full-year earnings forecast for the fiscal year ending December 2025, cutting projected sales revenue by ¥900 million to ¥400 million. The revision is driven primarily by delays in recognizing product sales of Sancuso in China due to extended customs and testing procedures following a manufacturing site change, the termination of a license agreement with FIREBIRD BIOLOGICS that eliminates expected upfront and milestone payments for DARVIAS and Episil, and the decision to exclude from its outlook any revenue tied to yet-unconcluded technology transfer and commercial license agreements for Sancuso in China beyond 2026. In addition, the company will return part of unrecognized upfront revenue from a Chinese Episil license with GenSci, though this will not affect profit or loss, underscoring that the main impact of these changes is a near-term revenue shortfall rather than an immediate hit to reported earnings, and highlighting ongoing uncertainty around the timing and structure of Solasia’s China-related partnership income.
More about Solasia Pharma KK
Solasia Pharma K.K. is a Japan-based biopharmaceutical company listed on the Tokyo Stock Exchange Growth Section that focuses on developing and commercializing specialty oncology-related therapies. Its portfolio includes products such as Sancuso (SP-01), a transdermal antiemetic patch, DARVIAS (SP-02), and Episil (SP-03), with a significant commercial focus on the Chinese market through licensing and partnership agreements.
Average Trading Volume: 50,107,186
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen7.56B
See more insights into 4597 stock on TipRanks’ Stock Analysis page.